Curevac N.V. buy Konafets
Start price
02.05.21
/
50%
€98.94
Target price
02.05.22
€123.00
Performance (%)
-74.88%
End price
13.01.22
€24.85
Summary
This prediction ended on 13.01.22 with a price of €24.85. Massive losses of -74.88% were the result for the BUY prediction by Konafets. Konafets has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Curevac N.V. | 5.450% | 5.450% | - | - |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
According to Konafets what are the pros and cons of Curevac N.V. for the foreseeable future?
Pros
Revenue growth >5% per year expected
Higher EBIT margin than peer group
positive Cash Flow expected
ROE higher than 10% per year
Capable Management
Good culture
Leading role in innovation
Differentiated customer and product portfolio
Growths faster than the competition
Very small cyclical dependencies
Known brand
Future proof or reliable business model
EBIT growth >5% per year expected
Fair valuation
Good rating
High Investments for future growth
Stable Large shareholder and/or long term investor
Could be worthwhile Investment >10% per year
Cons
Very low/no dividend yield expected
Few uniques
Risky balance sheet
Higher risks for its business